Federal Register / Vol. 70, No. 176 / Tuesday, September 13, 2005 / Notices 54053 

send comments to Seleda Perryman, 

CDC Assistant Reports Clearance 

Officer, 1600 Clifton Road, MS–D74, 

Atlanta, GA 30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Cycle 7 of the National Survey of 

Family Growth (NSFG–7)—OMB No. 

0920–0314—Reinstatement with 

change—National Center for Health 

Statistics (NCHS), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

The National Survey of Family 

Growth (NSFG) has been conducted 

periodically since 1973 by the CDC’s 

National Center for Health Statistics. 

The first five cycles were based on inperson interviews with national samples 

of women 15–44 years of age. Cycle 6, 

in 2002, was based on interviews with 

a national sample of 12,571 persons—

4,928 men and 7,643 women ages 15–

44. Interviews provided national 

estimates of behavior related to birth 

and pregnancy rates; marriage, divorce, 

and adoption; behavior related to the 

risk of Human Immunodeficiency Virus 

(HIV) and other sexually transmitted 

diseases; attitudes toward marriage, 

childbearing, and parenthood; and 

men’s and women’s roles in raising 

children. 

While the content of Cycle 7 will be 

similar to that of Cycle 6, the 

interviewing will be conducted over a 4- 

year period rather than being completed 

in one year, as in previous cycles. This 

continuous interviewing design is 

intended to reduce costs, increase 

efficiency, and contribute to continuous 

improvement in the collection, 

processing, and dissemination of the 

data. Sample size is expected to increase 

from 12,571 in Cycle 6 to 17,400 total 

in the 4 years of data collection in Cycle 

7. For this cycle, the ‘‘Pretest’’ will be 

conducted initially in the first 8 weeks 

of interviewing and, if no problems are 

found, those weeks will become part of 

the Main Study. If operational problems 

are found in that period, they will be 

corrected, and the ‘‘Main Study’’ will 

begin at that point. The burden table 

represents the survey collection 

averaged over the first three years of 

data collection. 

Users of the NSFG include: the 

National Institutes of Health’s National 

Institute of Child Health and Human 

Development and the Office of 

Population Affairs; CDC’s NCHS, 

Division of Reproductive Health, 

National Center for Chronic Disease 

Prevention and Health 

Promotion(NCCDPHP); Divisions of 

HIV/AIDS Prevention, National Center 

for HIV, STD, & TB Prevention 

(NCHSTP); and the Department’s Office 

of the Assistant Secretary for Planning 

and Evaluation, and Administration for 

Children and Families. There is no cost 

to respondents other than their time to 

participate. 

ESTIMATED AVERAGE ANNUALIZED HOUR BURDEN

Survey and type of respondents Number of 

respondents 

Responses 

per respondent 

Avg. burden 

per response 

(in hours) 

Total burden 

hours. 

Pretest 

Screener .......................................................................................................... 403 1 5/60 34

Males ............................................................................................................... 109 1 1 109

Females ........................................................................................................... 133 1 1.33 177 

Main Study 

Screener .......................................................................................................... 7,250 1 5/60 604 

Males ............................................................................................................... 1,957 1 1 1,957 

Females ........................................................................................................... 2,393 1 1.33 3,183 

Total .......................................................................................................... ........................ ........................ ........................ 6,064 

Betsey Dunaway, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 05–18056 Filed 9–12–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: 

Title: Financial Status Reporting Form 

for the Program of State Council on 

Developmental Disabilities. 

OMB No.: 098––0212. 

Description: For the program of the 

State Council on Developmental 

Disabilities, funds are awarded to State 

agencies contingent on fiscal 

requirements in Subtitle B of the 

Developmental Disabilities Assistance 

and Bill of Rights Act. The SF–269, 

ordinarily mandated in the revised OMB 

Circular A–102, provides no accounting 

breakouts necessary for proper 

stewardship. Consequently, the 

proposed streamlined form will 

substitute for the SF–269 and will allow 

compliance monitoring and proactive 

compliance maintenance and technical 

assistance. 

Respondents: State Councils and 

Designated State Agencies. 

54054 Federal Register / Vol. 70, No. 176 / Tuesday, September 13, 2005 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of responses per 

respondent 

Average burden hours per 

response 

Total burden 

hours 

Financial Status Reporting Form for program of State Council on Developmental Disabilities ........................................................................................ 55 1 8 440 

Estimated Total Annual Burden 

Hours: 440. 

In compliance with the requirements 

of section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447, Attn: ACF Reports Clearance 

Officer. E-mail address: 

grjohnson@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Dated: September 7, 2005. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 05–18045 Filed 9–12–05; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2005N–0354] 

Consumer-Directed Promotion of 

Regulated Medical Products; Public 

Hearing 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public hearing; request 

for comments. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

public hearing on direct-to-consumer 

(DTC) promotion of regulated medical 

products, including prescription drugs 

for humans and animals, vaccines, 

blood products, and medical devices. 

FDA is particularly interested in hearing 

the views of individuals and groups 

most affected by DTC promotion, 

including consumers, patients, 

caregivers, health professionals 

(physicians, physicians’ assistants, 

dentists, nurses, pharmacists, 

veterinarians, and veterinarian 

technicians) managed care 

organizations, and insurers, as well as 

the regulated industry. FDA is seeking 

input on a number of specific questions, 

but is interested in any other pertinent 

information participants in the hearing 

would like to share. 

Dates and Times: The public hearing 

will be held on November 1 and 2, 2005, 

from 9 a.m. to 5 p.m. Submit written or 

electronic notices of participation by 

close of business on October 11, 2005. 

Written and electronic comments will 

be accepted until February 28, 2006. 

Location: The public hearing will be 

held at the National Transportation 

Safety Board Boardroom and Conference 

Center, 429 L’Enfant Plaza, SW., 

Washington, DC 20594, 202–314–6421; 

Metro: L’Enfant Plaza station on the 

green, yellow, blue, and orange lines; 

see: http://ntsb.gov/events/ 

newlocation.htm. (FDA has verified the 

Web site address, but FDA is not 

responsible for any changes to the Web 

site after this document publishes in the 

Federal Register.) 

Addresses: Written or electronic 

notices of participation should be 

submitted to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852, or on the 

Internet at http:// 

www.accessdata.fda.gov/scripts/oc/ 

dockets/meetings/meetingdocket.cfm. 

Comments about the meeting or 

comments after the meeting should be 

submitted to http://www.fda.gov/ 

dockets/ecomments. Written or 

electronic comments can be submitted 

to http://www.fda.gov/oc/dockets/ 

ecomments. A consolidated list of all 

documents and other information 

related to the public hearing, such as the 

Federal Register notice, the agenda, 

public comments, and transcripts will 

be posted with their links, as the 

documents are made available, on the 

Center for Drug Evaluation and Research 

(CDER) Web site at http://www.fda.gov/ 

cder/ddmac. 

For further information contact: Rose 

Cunningham, Center for Drug 

Evaluation and Research (HFD–006), 

Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20852, 

301–443–5595, e-mail: 

cunninghmar@cder.fda.gov. 

For registration to attend and/or to 

participate in the meeting: Seating at the 

hearing is limited. People interested in 

attending the meeting should register at 

http://www.accessdata.fda.gov/scripts/ 

oc/dockets/meetings/ 

meetingdocket.cfm. Registration is free 

and will be accepted on a first-come, 

first-served basis. 

The procedures governing the hearing 

are found in part 15 (21 CFR part 15). 

Anyone wishing to make an oral 

presentation during the hearing must 

state this intention on the registration 

form (see Addresses). To participate, 

submit your name, title, business 

affiliation, address, telephone and fax 

numbers, and e-mail address. 

A written statement also should be 

submitted at the time of registration for 

each discussion question to be 

addressed, with the names and 

addresses of all individuals who plan to 

participate, and the approximate time 

requested for the presentation. The 

agency requests that interested persons 

and groups having similar interests 

consolidate their comments and present 

them through a single representative. 

Individuals who have registered to make 

an oral presentation will be notified of 

the scheduled time for their 

presentation prior to the hearing. 

Depending on the number of 

presentations, FDA may need to limit 

the time allotted for each presentation. 

FDA has identified questions and 

subject matter of special interest in 

section III of this document, but 

presentations do not have to be limited 

to those questions. Presenters should